Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
ARV-393 targets and breaks down a protein called BCL6. This protein is found in cancer cells and plays a role in their growth and survival. By breaking down BCL6, ARV-393 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
The usual treatment for brain metastases (cancer that spread to the brain) is a single treatment of stereotactic radiosurgery (SRS). SRS uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor.
In this study, researchers want to see if enzalutamide, alone or with mifepristone, works well against advanced breast cancer. The people in this study have either triple-negative breast cancer (TNBC) or cancer that is low in estrogen receptors (ER). Receptors are docking sites on cancer cells for hormones or other proteins. TNBC is breast cancer that is not fueled by estrogen or progesterone and does not make a protein called HER2. The people in this study also have cancer cells that have receptors for proteins called androgens (AR-positive cancers).
The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.
Researchers are comparing different treatments for triple-negative breast cancer (TNBC). The people in this study have TNBC that has been surgically removed.
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
Researchers want to find the best dose of BDTX-4933 to use in people with advanced lung cancer. The people in this study have non-small cell lung cancer that has a mutation (change or variant) in the BRAF or KRAS genes (KRAS non-G12C mutation). This mutation can cause cancer cells to grow.
